A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma

Valerie B. Sampson, Richard Gorlick, Davida Kamara, E. Anders Kolb

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in children and the fully human monoclonal antibody, anti-GD2, as part of an immune therapy for high-risk neuroblastoma patients have established the precedent for use of targeted inhibitors along with standard chemotherapy backbones. However, few targeted agents tested have achieved traditional clinical endpoints for osteosarcoma. Many biological agents demonstrating anti-tumor responses in preclinical and early-phase clinical testing have failed to reach response thresholds to justify randomized trials with large numbers of patients. The development of targeted therapies for pediatric cancer remains a significant challenge. To aid in the prioritization of new agents for clinical testing, the Pediatric Preclinical Testing Program (PPTP) has developed reliable and robust preclinical pediatric cancer models to rapidly screen agents for activity in multiple childhood cancers and establish pharmacological parameters and effective drug concentrations for clinical trials. In this article, we examine a range of standard and novel agents that have been evaluated by the PPTP, and we discuss the preclinical and clinical development of these for the treatment of osteosarcoma. We further demonstrate that committed resources for hypothesis-driven drug discovery and development are needed to yield clinical successes in the search for new therapies for this pediatric disease.

Original languageEnglish (US)
Article numberArticle 132
JournalFrontiers in Oncology
Volume3 MAY
DOIs
StatePublished - 2013

Fingerprint

Osteosarcoma
Pediatrics
Neoplasms
Therapeutics
Bone and Bones
Drug Therapy
Philadelphia Chromosome
Biological Factors
Drug Discovery
Neuroblastoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sarcoma
Monoclonal Antibodies
Clinical Trials
Pharmacology
Pharmaceutical Preparations

Keywords

  • Complete response
  • Event-free survival
  • Maintained complete response
  • Osteosarcoma
  • Partial response
  • Pediatric preclinical testing program
  • Progressive disease
  • Progressive disease with growth delay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. / Sampson, Valerie B.; Gorlick, Richard; Kamara, Davida; Kolb, E. Anders.

In: Frontiers in Oncology, Vol. 3 MAY, Article 132, 2013.

Research output: Contribution to journalArticle

Sampson, Valerie B. ; Gorlick, Richard ; Kamara, Davida ; Kolb, E. Anders. / A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. In: Frontiers in Oncology. 2013 ; Vol. 3 MAY.
@article{5f4833e167c94062a6f3cfafbd8c3561,
title = "A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma",
abstract = "Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in children and the fully human monoclonal antibody, anti-GD2, as part of an immune therapy for high-risk neuroblastoma patients have established the precedent for use of targeted inhibitors along with standard chemotherapy backbones. However, few targeted agents tested have achieved traditional clinical endpoints for osteosarcoma. Many biological agents demonstrating anti-tumor responses in preclinical and early-phase clinical testing have failed to reach response thresholds to justify randomized trials with large numbers of patients. The development of targeted therapies for pediatric cancer remains a significant challenge. To aid in the prioritization of new agents for clinical testing, the Pediatric Preclinical Testing Program (PPTP) has developed reliable and robust preclinical pediatric cancer models to rapidly screen agents for activity in multiple childhood cancers and establish pharmacological parameters and effective drug concentrations for clinical trials. In this article, we examine a range of standard and novel agents that have been evaluated by the PPTP, and we discuss the preclinical and clinical development of these for the treatment of osteosarcoma. We further demonstrate that committed resources for hypothesis-driven drug discovery and development are needed to yield clinical successes in the search for new therapies for this pediatric disease.",
keywords = "Complete response, Event-free survival, Maintained complete response, Osteosarcoma, Partial response, Pediatric preclinical testing program, Progressive disease, Progressive disease with growth delay",
author = "Sampson, {Valerie B.} and Richard Gorlick and Davida Kamara and Kolb, {E. Anders}",
year = "2013",
doi = "10.3389/fonc.2013.00132",
language = "English (US)",
volume = "3 MAY",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma

AU - Sampson, Valerie B.

AU - Gorlick, Richard

AU - Kamara, Davida

AU - Kolb, E. Anders

PY - 2013

Y1 - 2013

N2 - Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in children and the fully human monoclonal antibody, anti-GD2, as part of an immune therapy for high-risk neuroblastoma patients have established the precedent for use of targeted inhibitors along with standard chemotherapy backbones. However, few targeted agents tested have achieved traditional clinical endpoints for osteosarcoma. Many biological agents demonstrating anti-tumor responses in preclinical and early-phase clinical testing have failed to reach response thresholds to justify randomized trials with large numbers of patients. The development of targeted therapies for pediatric cancer remains a significant challenge. To aid in the prioritization of new agents for clinical testing, the Pediatric Preclinical Testing Program (PPTP) has developed reliable and robust preclinical pediatric cancer models to rapidly screen agents for activity in multiple childhood cancers and establish pharmacological parameters and effective drug concentrations for clinical trials. In this article, we examine a range of standard and novel agents that have been evaluated by the PPTP, and we discuss the preclinical and clinical development of these for the treatment of osteosarcoma. We further demonstrate that committed resources for hypothesis-driven drug discovery and development are needed to yield clinical successes in the search for new therapies for this pediatric disease.

AB - Osteosarcoma, the most common malignant bone tumor of childhood, is a high-grade primary bone sarcoma that occurs mostly in adolescence. Standard treatment consists of surgery in combination with multi-agent chemotherapy regimens. The development and approval of imatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in children and the fully human monoclonal antibody, anti-GD2, as part of an immune therapy for high-risk neuroblastoma patients have established the precedent for use of targeted inhibitors along with standard chemotherapy backbones. However, few targeted agents tested have achieved traditional clinical endpoints for osteosarcoma. Many biological agents demonstrating anti-tumor responses in preclinical and early-phase clinical testing have failed to reach response thresholds to justify randomized trials with large numbers of patients. The development of targeted therapies for pediatric cancer remains a significant challenge. To aid in the prioritization of new agents for clinical testing, the Pediatric Preclinical Testing Program (PPTP) has developed reliable and robust preclinical pediatric cancer models to rapidly screen agents for activity in multiple childhood cancers and establish pharmacological parameters and effective drug concentrations for clinical trials. In this article, we examine a range of standard and novel agents that have been evaluated by the PPTP, and we discuss the preclinical and clinical development of these for the treatment of osteosarcoma. We further demonstrate that committed resources for hypothesis-driven drug discovery and development are needed to yield clinical successes in the search for new therapies for this pediatric disease.

KW - Complete response

KW - Event-free survival

KW - Maintained complete response

KW - Osteosarcoma

KW - Partial response

KW - Pediatric preclinical testing program

KW - Progressive disease

KW - Progressive disease with growth delay

UR - http://www.scopus.com/inward/record.url?scp=84885779270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885779270&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00132

DO - 10.3389/fonc.2013.00132

M3 - Article

AN - SCOPUS:84885779270

VL - 3 MAY

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 132

ER -